Loading...
NPI 1598142895 · Mobile, AL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Synergy Laboratories, Inc. is a clinical medical laboratory provider located in Mobile, Alabama. This profile covers 134 Medicare and 123 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Synergy Laboratories, Inc. |
| Address | 5570 Rangeline Rd |
| City | Mobile |
| State | AL |
| ZIP | 36619 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 6, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $10.3M |
| Medicare | $2.4M |
Provider-level payer mix shows Medicaid dominance: SYNERGY LABORATORIES, INC. reports $10.3M in lifetime Medicaid revenue versus $2.4M in lifetime Medicare revenue, indicating Medicaid is the primary source of billed volume and cashflow for this lab. This scale difference suggests commercial/Medicaid contracting and state program relationships are likely more material to the business than Medicare reimbursement.
Revenue concentration is high on a small number of services for both payers: the top 3 Medicare codes account for 47.8% of the provider's Medicare revenue, and the top 3 Medicaid codes account for 59.5% of its Medicaid revenue. For Medicare the single largest code is G0480 (30.1% of Medicare revenue, $649.1K), while for Medicaid the single largest code is U0003 (25.0% of Medicaid revenue, $2.3M), underscoring dependence on a few high-volume/test types.
The code mix signals a dual service-line focus on definitive/presumptive drug testing and high-throughput infectious disease testing: G0480, G0481, and 80307 appear among the top Medicare codes and G0481 and 80307 are also top Medicaid drivers, while U0003, 87635 and multiple amplified nucleic acid codes (e.g., 87801, 87631) drive large Medicaid COVID/infectious-test revenue. This pattern is consistent with a clinical laboratory structured to process very high specimen volumes for substance testing and molecular infectious-agent detection rather than a narrow specialty pathology practice.
SYNERGY is a national outlier on at least one high-complexity drug-testing CPT/HCPCS: Medicare G0480 shows $649.1K revenue and ranks #22 of 1590 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code), indicating an unusually large market share of high-complexity definitive drug testing at the national level. At the same time several routine chemistry and hematology panels (e.g., 80053, 80061, 84443, 85025) also appear in high national percentiles (many at the 99th percentile), which points to broad, high-volume processing capacity across common lab panels.
State-level competitive standing is strong for high-volume Medicaid services: Medicaid G0481 ($1.7M) ranks #2 of 18 providers in-state (94th percentile; notably above typical state volume) and Medicaid 80307 ($1.5M) ranks #2 of 100 providers in-state (99th percentile; notably above typical state volume), while U0003 ($2.3M) ranks #4 of 65 in-state (95th percentile; typical, unremarkable volume). These ranks indicate SYNERGY is a leading in-state provider for both definitive drug testing and high-throughput COVID PCR work.
Claims counts confirm high throughput operations in Medicaid: U0003 shows 41.3K claims, G0481 shows 23K claims, and 80307 shows 35K claims, each contributing materially to the $10.3M Medicaid total. Those raw-claim volumes imply significant daily specimen handling and reporting capacity, which has implications for lab staffing, logistics, and payer adjudication workloads.
Tenure is established but relatively recent: the NPI was enumerated 2015-05-06 (~11 years ago), indicating the lab scaled to its current volume within roughly a decade. That timeline is consistent with rapid expansion into high-volume molecular and drug-testing services during the COVID era and subsequent years.
From a payer-operations perspective, the combination of large Medicaid scale, high claim counts on a few codes, and outlier national rank for G0480 creates both negotiation leverage and concentration risk: roughly 59.5% of Medicaid revenue is captured by the top three Medicaid codes and 47.8% of Medicare revenue by the top three Medicare codes, so changes in coverage, pricing, or utilization rules for these specific codes could disproportionately affect the provider's revenue. Payers evaluating network strategy should flag G0480, G0481, 80307 and U0003 for focused contract and utilization review given their outsized contribution to this provider's book of business.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
134 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,900 | $110 | $649.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,190 | $60 | $191.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,270 | $150 | $189.7K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 13,470 | $10 | $175.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 17,090 | $10 | $170.9K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 7,620 | $20 | $121.9K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 10,940 | $10 | $87.5K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 2,410 | $30 | $69.7K |
| 84153 | The lab analyst performs testing for total prostate specific antigen, PSA, typically on serum or plasma samples using laboratory analyzers. PSA is a protein the prostate gland produces, and… | 3,380 | $20 | $60.8K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 5,460 | $10 | $49.1K |
Showing 1–10 of 134
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 134 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
123 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 41,300 | $60 | $2.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 23,000 | $70 | $1.7M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 35,000 | $40 | $1.5M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 12,860 | $40 | $565.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12,270 | $40 | $503.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,050 | $110 | $453.5K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 7,520 | $40 | $278.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,220 | $80 | $172.8K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 12,950 | $10 | $168.4K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 9,190 | $20 | $156.2K |
Showing 1–10 of 123
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
123 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80081 | The lab analyst performs an obstetric panel; this panel must include tests for a complete blood count with differential, a hepatitis B surface antigen test, a single–result test for HIV–1 antigens… | 2 | 10 | 1,300 | $40 | $1.8M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 21 | 60 | 1,260 | $60 | $1.2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 6 | 20 | 160 | $20 | $1.1M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4 | 70 | 380 | $60 | $893.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 9 | 40 | 450 | $20 | $591.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 7 | 40 | 460 | $20 | $584.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 7 | 40 | 1,540 | $10 | $397.4K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 4 | 40 | 430 | $10 | $391.5K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 26 | 40 | 1,440 | $20 | $372.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 8 | 90 | 500 | $40 | $303.6K |
Showing 1–10 of 123
Other providers in the same ZIP code as Synergy Laboratories, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Gulf Coast Pediatrics, LLC | AL | Pediatrics Physician | $0 | $2.5M |
| Lisa Allsup | AL | Family Nurse Practitioner | $48.6K | $0 |
| Sara Beck | AL | Occupational Therapist | $23.2K | $0 |
| Three Notch Pharmacy LLC | AL | Community/Retail Pharmacy | $4.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.